Debra BorchardtFebruary 6, 2023
PharmaAla to supply the MDMA.
Tag: Revive Therapeutics
Debra BorchardtFebruary 6, 2023
Adam JacksonSeptember 16, 2022
Oral psilocybin film-strips to treat could conduct the first-in-human clinical study as soon as next year.
StaffJune 27, 2022
Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) gave an update last week on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Following Revive receiving positive comments from […]
Dave HodesMay 31, 2022
The shuffling of psychedelics companies into and out of success as shown in their respective quarterly earnings and annual reports over the last few weeks offers a glimpse into what it takes to survive and thrive in the industry. The strategic acquisition, development of novel therapeutics, and building awareness and collaborations are the names of […]
StaffJanuary 21, 2021
No sooner had Revive Therapeutics Ltd. (OTC: RVVTF) announce it had raised $10, then it stopped trading to say the deal was upsized to $20 million. Revive is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. The company entered into an agreement with Canaccord Genuity […]
Debra BorchardtApril 29, 2020
Specialty life science company Revive Therapeutics Ltd. (CSE: RVV) has said that it will investigate novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, based on its wholly-owned patent-pending psilocybin formulations and its exclusive licensed drug delivery technology from the Wisconsin Alumni Research Foundation. “We are expanding our psilocybin-based pharmaceutical […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.